Phase 1 Clinical Trial to Evaluate the Safety of FURESTEM-RA Inj. in Patients With Moderate to Severe Rheumatoid Arthritis

Trial Profile

Phase 1 Clinical Trial to Evaluate the Safety of FURESTEM-RA Inj. in Patients With Moderate to Severe Rheumatoid Arthritis

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Nov 2016

At a glance

  • Drugs Umbilical cord mesenchymal stem cell therapy-Kangstem Holdings (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Proof of concept
  • Acronyms CURE-iv
  • Sponsors Kangstem Holdings
  • Most Recent Events

    • 20 Oct 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Mar 2015 Planned End Date changed from 1 Sep 2015 to 1 Dec 2015, as reported by ClinicalTrials.gov.
    • 17 Mar 2015 Planned primary completion date changed from 1 Jul 2015 to 1 Oct 2015, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top